RXI PHARMACEUTICALS CORPORATION

Basic Information

1500 West Park Drive
Suite 210
Westborough, MA, 01581-

Company Profile

n/a

Additional Details

Field Value
DUNS: 932221729
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Development of sd-rxRNAs as Therapy for Retinoblastoma and Other Malignancies

    Amount: $292,272.00

    DESCRIPTION (provided by applicant): The study of retinoblastoma, a childhood tumor, has provided numerous insights into cancer biology. Perhaps most significantly, this work has revealed that cancers ...

    SBIR Phase I 2012 Department of Health and Human Services
  2. Improving self delivering properties of RNAi compounds through medicinal chemistr

    Amount: $273,824.00

    DESCRIPTION (provided by applicant): Introduction of small interfering RNAs (siRNAs) into cells with transfection reagents results in potent and specific gene silencing by RNA interference (RNAi). Unf ...

    SBIR Phase I 2011 Department of Health and Human Services
  3. Novel RNAi therapy for ALS and other Neurodegenerative Disorders

    Amount: $304,559.00

    DESCRIPTION (provided by applicant): Project Summary / Abstract Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting motor neurons in the central nervous syste ...

    SBIR Phase I 2011 Department of Health and Human Services
  4. Orally administered anti-TNFalpha RNAi therapeutic for autoimmune disorders

    Amount: $597,088.00

    DESCRIPTION (provided by applicant): Introduction of small interfering RNAs (siRNAs) into cells results in potent and specific gene silencing by RNA interference (RNAi). Unfortunately, while siRNA-bas ...

    SBIR Phase I 2010 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government